Congress Should Not Impose Foreign Price Controls On Innovative Drugs
By: bitcoin ethereum news|2025/05/04 09:00:01
0
Share
VALUE and PRICE balancing Simple and neat solutions are alluring but often wrong. A case in point is President Trump’s proposal to adopt a most favored nation (MFN) policy. The MFN sets Medicaid’s price for a drug at the lowest price charged in other developed countries each of which has price controls on drugs. If implemented, this policy will make a bad situation much worse. The logic for implementing the MFN is simple – if patients in the U.K. or Canada are paying less money for a drug, then so should patients in the U.S. But the prices for innovative drugs in many OECD countries are only lower because these nations impose strict price controls, which always come with a high cost. To start with, price controls diminish drug availability. Thanks to price controls, patients in the other major industrialized countries (OECD) have access to only 29% of new medicines while patients in the U.S. have access to 85%. Even worse, patients in Canada and the U.K. can wait years for access to the latest treatments in some cases, and at any given time in Canada, there is a shortage of between 1,500 and 2,000 drugs. In those cases where the drugs are available in foreign nations, adopting the MFN policy outsources U.S. health policy to these countries. The U.S. should not impose price controls, but if it does, drug pricing decisions should not be outsourced to the EU, UK, or Canada. Adopting the MFN will also harm innovation. Developing a new drug takes a lot of time and money. On average, developing one innovative drug takes over $2.9 billion (including post-marketing expenditure) and between 10 and 15 years. It is also a risky endeavor. Approximately 9 out of every 10 drugs that reach the clinical trial stage will ultimately fail. Drug price controls make it harder for innovative firms to cover their capital costs, which reduces the amount of money spent on new innovations. A University of Chicago Issue Brief by Philipson and Durie found “that a 1 percent reduction in revenue leads to a 1.5 percent reduction in R&D activity.” The consequences from disincentivizing innovation would hit the U.S. economy hard. According to the latest industry economic impact report, the biotechnology industry directly contributed $1.4 trillion to the economy in 2023 (around 6.8% of the private sector GDP), supported nearly 2.3 million jobs, and paid hundreds of billions of dollars in taxes to the federal government. Perhaps even more important, the lost innovation from price controls harms patients currently living with diseases that have inadequate or no treatment options. If price controls are adopted in the U.S., then patients living with Alzheimer’s disease, pancreatic cancer, or muscular dystrophy may end up waiting in vain for efficacious treatments. Ultimately, the problem is that foreign governments are imposing price controls on drugs. The result is that patients across the globe benefit from American pharmaceutical innovation without paying their fair share of the innovation’s costs. The best way to address this problem is to defend the intellectual property of U.S. firms in trade negotiations. Executing on this goal could include appointing a pharmaceutical trade negotiator at USTR to defend American companies’ interests. Successfully concluding these negotiations is a long-term project, however. There are beneficial reforms that Congress can implement now that will promote greater drug availability in the meantime. These reforms should address the many inefficiencies that plague the U.S. drug market. For instance, more than half of the revenues from drug sales goes to hospitals, pharmacies, and other middlemen thanks to errant policies. These errant policies include the 340B drug discount program, which now has the contradictory impact of raising overall drug prices. Reforms should demand greater transparency in the program and mandate 340B only serves its intended population. These changes will improve 340B’s effectiveness while relieving the inflationary price pressures created by the program. Another necessary reform would address the current opaque drug pricing system that is empowering pharmacy benefit managers (PBMs) to the detriment of patients. Thanks to the system’s misaligned incentives, costs are being inequitably shifted to patients. Worsening the problem, the system often encourages the use of more expensive medicines rather than lower cost alternatives. Reining in PBMs will improve the drug market’s incentives resulting in lower out-of-pocket costs for patients without diminishing the incentives for innovation. The FDA approval process is also slow and overly burdensome. Reforming this process can lower the cost of developing new treatments while expediting their availability to patients. The goal of U.S. drug policy should be to promote the dual goals of innovation and broad-based affordability. The MFN policy adopts foreign imposed price controls that will discourage innovation and reduce patients access to medicines. While spending on medicine may go down, total healthcare spending is likely to increase as patients wind up requiring more expensive surgeries and hospital stays. Promoting more affordable drugs is not simple. It requires the hard work of understanding what is driving the problem and implementing policies that directly fix them. The MFN is a shortcut that patients will quickly come to regret. Source: https://www.forbes.com/sites/waynewinegarden/2025/05/03/congress-should-not-impose-foreign-price-controls-on-innovative-drugs/
You may also like

Exchanging 200,000 for nearly 100 million, DeFi stablecoins face another attack
DeFi project teams cannot assume that the modules they control are necessarily secure.

The underlying business agreement of the trillion-dollar Agent economy: Understanding ERC-8183, it's not just about payments, but the future
This article systematically analyzes the technical principles and commercial value of the ERC-8183 protocol from the dimensions of technical architecture, core mechanisms, application scenarios, and ecological collaboration.

When Wall Street's ETH begins to "yield": Looking at the asset properties of Ethereum from BlackRock's ETHB
ETH is undergoing a paradigm shift from a "volatile asset" to a "yield-generating cash flow asset."

The Power of Agency: The Agentic Wallet and the Next Decade of Wallets
In 1984, Apple killed the command line with a mouse. In 2026, Agent is killing the mouse.

Understanding x402 and MPP in One Article: Two Routes for Agent Payments
x402 makes payments within the agreement, while MPP makes system-level payments.

Particle Founder: The entrepreneurial insights I have gained the most from in the past year
Stop lean startup, stop lightning entrepreneurship, and think carefully about what your product aspirations are.

Huang Renxun's latest podcast transcript: The future of Nvidia, the development of embodied intelligence and agents, the explosion of inference demand, and the public relations crisis of artificial intelligence
The competition in the future is not just about whose model is larger or whose computing power is stronger, but also about who understands the industry better, who can embed AI more deeply into real processes, and who can organize these capabilities into a runnable and scalable system.

OKX Ventures Research Report: AI Agent Economic Infrastructure Research Report (Part 1)
The existing infrastructure is hostile to the Agent economy. Agents can think and act independently at the "capability level," but at the "economic level," they are still locked into infrastructure designed for humans.

The migration of settlement rights: B18 and the institutional starting point of on-chain banks
In the traditional system, banks decide the settlement; in the on-chain system, code begins to take over this responsibility.

From Tencent and Circle: Looking at the Simple and Difficult Questions of Investment
The AI narrative continues to ferment, but the recent performance of related stocks varies, with some in the midst of summer and others as if in winter.

The second half of stablecoins no longer belongs to the crypto circle
What Coinbase doesn't want, Mastercard is eager to buy.

Cursor "Shell" Kimi Controversy Reversed: From Copyright Infringement Allegations to Authorized Collaboration, China's Open Source Model Once Again Becomes a Global AI Foundation
Cursor was accused of being based on Kimi K2.5, which sparked controversy, and was later confirmed to be compliant through Fireworks AI due diligence.

The Real Reason Tokens Don't Sell: 90% of Crypto Projects Overlook Investor Relations
Provide an Investor Relations Best Practices Guide for Crypto Projects.

Is the income of pump.fun real, earning a million dollars a day despite the market downturn?
If it can really earn this much, what is the reason for the low price of $PUMP?

The real reason why tokens are not selling: 90% of crypto projects neglect investor relations
Investor Relations Practice Guide for Cryptocurrency Projects.

Who is the true winner of the "Tokenization" narrative?
Virtually everyone benefits, but the reason for the benefit, the timing, and the underlying logic are completely different.

Moss: The Era of AI-Traded by Anyone | Project Introduction
AI Trading Agent is rapidly growing its infrastructure.

Chip Smuggling Case Exposes Regulatory Loophole | Rewire News Evening Update
AI chips have become a strategic asset more sensitive than missiles
Exchanging 200,000 for nearly 100 million, DeFi stablecoins face another attack
DeFi project teams cannot assume that the modules they control are necessarily secure.
The underlying business agreement of the trillion-dollar Agent economy: Understanding ERC-8183, it's not just about payments, but the future
This article systematically analyzes the technical principles and commercial value of the ERC-8183 protocol from the dimensions of technical architecture, core mechanisms, application scenarios, and ecological collaboration.
When Wall Street's ETH begins to "yield": Looking at the asset properties of Ethereum from BlackRock's ETHB
ETH is undergoing a paradigm shift from a "volatile asset" to a "yield-generating cash flow asset."
The Power of Agency: The Agentic Wallet and the Next Decade of Wallets
In 1984, Apple killed the command line with a mouse. In 2026, Agent is killing the mouse.
Understanding x402 and MPP in One Article: Two Routes for Agent Payments
x402 makes payments within the agreement, while MPP makes system-level payments.
Particle Founder: The entrepreneurial insights I have gained the most from in the past year
Stop lean startup, stop lightning entrepreneurship, and think carefully about what your product aspirations are.